Australia markets close in 2 hours 30 minutes
  • ALL ORDS

    7,751.60
    +5.70 (+0.07%)
     
  • ASX 200

    7,543.90
    +4.90 (+0.06%)
     
  • AUD/USD

    0.6916
    +0.0025 (+0.37%)
     
  • OIL

    74.83
    +0.72 (+0.97%)
     
  • GOLD

    1,885.70
    +6.20 (+0.33%)
     
  • BTC-AUD

    32,993.48
    -432.32 (-1.29%)
     
  • CMC Crypto 200

    523.49
    -1.64 (-0.31%)
     
  • AUD/EUR

    0.6437
    +0.0024 (+0.38%)
     
  • AUD/NZD

    1.0927
    +0.0009 (+0.08%)
     
  • NZX 50

    12,137.55
    -59.60 (-0.49%)
     
  • NASDAQ

    12,464.51
    -108.85 (-0.87%)
     
  • FTSE

    7,836.71
    -65.09 (-0.82%)
     
  • Dow Jones

    33,891.02
    -34.99 (-0.10%)
     
  • DAX

    15,345.91
    -130.52 (-0.84%)
     
  • Hang Seng

    21,446.85
    +224.69 (+1.06%)
     
  • NIKKEI 225

    27,741.77
    +48.12 (+0.17%)
     

AFT Pharmaceuticals First Half 2023 Earnings: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

AFT Pharmaceuticals (NZSE:AFT) First Half 2023 Results

Key Financial Results

  • Revenue: NZ$65.8m (up 18% from 1H 2022).

  • Net income: NZ$1.45m (down 66% from 1H 2022).

  • Profit margin: 2.2% (down from 7.6% in 1H 2022). The decrease in margin was driven by higher expenses.

  • EPS: NZ$0.01 (down from NZ$0.04 in 1H 2022).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

AFT Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in Oceania.

Performance of the market in New Zealand.

The company's shares are down 2.4% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with AFT Pharmaceuticals.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here